Clinical and Diagnostic Laboratory Immunology, March 1999, p. 178-180, Vol. 6, No. 2
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Timing of Development of Measles-Specific
Immunoglobulin M and G after Primary Measles Vaccination
Rita F.
Helfand,1,*
Senait
Kebede,2
Howard E.
Gary Jr.,1
Hagos
Beyene,2 and
William
J.
Bellini1
Division of Viral and Rickettsial Diseases,
National Center for Infectious Diseases, Centers for Disease
Control and Prevention, Atlanta, Georgia 30333,1
and Department of Pediatrics, Addis Ababa University,
Addis Ababa, Ethiopia2
Received 28 September 1998/Returned for modification 4 November
1998/Accepted 18 November 1998
 |
ABSTRACT |
A standard method for diagnosing measles is to detect
measles-specific immunoglobulin M (IgM) in the serum of infected
persons. Interpreting a positive IgM result from a person with
suspected measles can be difficult if the person has recently received
a measles vaccine. We have previously demonstrated that
measles-specific IgM may persist for at least 8 weeks after primary
vaccination, but it is unknown how quickly IgM appears. This study
determined the timing of the rise of measles-specific IgM and IgG after
primary measles vaccination with Schwartz vaccine. Two hundred eighty 9-month-old children from Ethiopia presenting for routine measles vaccination were enrolled. Sera were collected before and either 1, 2, 3, or 4 weeks after vaccination and tested for measles-specific antibodies by an IgM capture enzyme immunoassay (EIA) and by an indirect IgG EIA. A total of 209 of the 224 children who returned for
the second visit had prevaccination sera that were both IgM and IgG
negative. The postvaccination IgM positivity rates for these 209 children were 2% at 1 week, 61% at 2 weeks, 79% at 3 weeks, and 60%
at 4 weeks. The postvaccination IgG positivity rates were 0% at 1 week, 14% at 2 weeks, 81% at 3 weeks, and 85% at 4 weeks. We
conclude that an IgM-positive result obtained by this antibody capture
EIA is difficult to interpret if serum is collected between 8 days and
8 weeks after vaccination; in this situation, the diagnosis of measles
should be based on an epidemiologic linkage to a confirmed case or on
the detection of wild-type measles virus.
 |
INTRODUCTION |
The detection of measles-specific
immunoglobulin M (IgM) has become a standard diagnostic method for the
laboratory confirmation of measles infection. A previous study of
persons who developed detectable measles IgM after natural measles
infection demonstrated that 77% developed IgM within 72 h after
rash onset and 100% developed IgM at 4 to 11 days after rash onset.
Moreover, more than 90% of persons remained IgM positive for 28 days
(7). The interpretation of positive IgM results from persons
with suspected natural measles infections becomes more difficult if
these persons have been vaccinated recently. The timing of the rise and
decline of measles IgM in the first 4 weeks after primary vaccination
has not been well documented. We recently demonstrated that measles IgM
declines rapidly between 4 and 8 weeks after primary measles
vaccination (6). However, the rate of IgM positivity was
lower than expected at 4 weeks, raising the possibility that IgM is
already declining by 4 weeks. In this report, we evaluate the kinetics
of measles-specific IgM and IgG in the first 4 weeks after primary
measles vaccination.
 |
MATERIALS AND METHODS |
The sera for this report were part of a study to evaluate the
comparative detection of measles-specific IgM antibodies in serum and
oral fluid samples after primary measles vaccination. The study group
consisted of 280 9-month-old infants presenting for routine measles
vaccination to Tekle Haimanot Health Centre, Addis Ababa, Ethiopia,
between August 1996 and January 1997. After informed consent was
obtained, sera (by heel stick) and oral fluid samples were collected
before and either 1, 2, 3, or 4 weeks after routine measles vaccination
(Schwartz vaccine). Infants were enrolled into sequential weeks
according to when they presented for measles vaccination (e.g.,
subjects 1 through 4 were enrolled into weeks 1 through 4, respectively; subjects 5 through 8 were enrolled into weeks 1 through
4, etc.). Samples were frozen at
70°C and shipped to the Centers
for Disease Control and Prevention (CDC) on dry ice. The comparison of
serum and oral fluid samples will be reported separately in the future.
At CDC, serum samples were tested for measles-specific IgM antibodies
by using a monoclonal-based antibody-capture enzyme immunoassay (EIA)
(8). Microtiter plates were coated with goat anti-human IgM
antibodies diluted in phosphate-buffered saline (PBS), incubated for
1 h at 37°C, and then washed. Next, serum diluted 1:200 in PBS
with 0.5% gelatin and 0.15% Tween 20 (PBS-GT) was added to four
consecutive wells. The plates were then incubated for 1 h at
37°C and washed. Baculovirus-measles virus nucleoprotein or
sf9-uninfected cell control lysate diluted in PBS-GT with 4% normal
goat serum and 0.3% sodium deoxycholate was added to duplicate wells.
The plates were then incubated for 2 h at 37°C and washed. Biotinylated monoclonal antibody (83VIIKK2) in PBS-GT was added to the
plates, and the plates were incubated for 1 h at 37°C and washed. The plates were then incubated at 37°C with
streptavidin-peroxidase in PBS-GT for 20 min and washed again.
Tetramethylbenzidine substrate was added for 15 min, and the reaction
was stopped by acidification. Finally, optical densities for
antigen-positive and antigen-negative wells were determined photometrically.
IgM-EIA results were expressed as the average difference in measured
optical density values between duplicate wells of positive antigen (P)
and negative tissue culture control antigen (N). Although the presence
of prevaccination sera made it possible to calculate study-specific
cutoff values, we chose to use standard cutoff values to be consistent
with our reporting practices of individual samples received for
diagnostic testing. These standard cutoff values were calculated
previously to maximize specificity and to take into account run-to-run
variability. Specifically, a sample was considered IgM positive if
P
N was
0.10 and P/N was
3. A sample was considered IgM
borderline if either (i) P
N was
0.09 but <0.10 and P/N was
3 or (ii) P
N was
0.10 and P/N was
2 but <3. Sera were
also tested for the presence of measles-specific IgG antibodies by
using an indirect EIA (3, 8). The standard IgG cutoff values
used were as follows. A sample was considered positive if P
N
was
0.09 and P/N
3, and a sample was considered borderline if
either (i) P
N was
0.08 but <0.09 and P/N was
3 or (ii)
P
N was
0.09 and P/N was
2 but <3.
 |
RESULTS |
Two hundred twenty-four (80%) of the 280 enrolled children
returned and had serum collected during the second visit. The median age at vaccination was 9.4 months (range, 7.3 to 13.0 months), and 111 (49.6%) of the children were males.
Two hundred and nine (93.3%) of the 224 children were both IgM and IgG
negative prior to vaccination. Table 1
displays IgM and IgG results by week after vaccination for these 209 children. Approximately 50 children returned for follow-up visits each
week during the first 4 weeks after vaccination. In week 1, 98% and 100% of samples were IgM negative and IgG negative, respectively. The
ratio of IgM-positive samples reached 61% at week 2, peaked at 79% in
week 3, and declined to 60% in week 4. As expected, the highest rate
of IgG positivity occurred in weeks 4 and 5. The timing of the IgM and
IgG responses is demonstrated graphically in Fig.
1a and b, which show the optical
densities (P
N) for IgM and IgG by time since vaccination for
the 209 children. The optical densities peaked at week 3 for IgM and
were declining at week 4. As expected, the IgG optical densities rose
more slowly.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Percentage of persons with measles-specific IgM and IgG
by week after measles vaccination for the 209 children who were IgM-
and IgG-negative prior to vaccination
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 1.
(a) Difference in IgM optical densities of positive and
negative (P N) wells for each infant by week after measles
vaccination. The larger dashed line represents the 50th percentile for
each week (a week was defined as a multiple of 7 ± 3 days; e.g.,
week 2 = 11 to 17). The horizontal dashed line represents the
cutoff P N value of 0.10, which was used in combination with
the P/N ratio to determine whether the specimen was considered IgM
positive, IgM borderline, or IgM negative. (b) Difference in IgG
optical densities of P N wells for each infant by week after
vaccination. As in panel a, the larger dashed line represents the 50th
percentile for each week, and the horizontal dashed line represents the
cutoff P N value of 0.09. Both graphs include only data for
infants who were both IgM and IgG negative before vaccination.
|
|
Fifteen children had prevaccination samples that were not negative for
both IgM and IgG: three had uninterpretable IgG results because of high
background; five were IgG positive and four had borderline IgG results
(all nine were IgM negative); two were IgM positive but IgG negative;
and one was both IgM positive and IgG positive. After vaccination,
three children continued to have uninterpretable IgG results (one was
IgM negative in week 1 after vaccination and two were IgM positive in
week 3 after vaccination). Ten of the remaining 12 children were IgG
positive after vaccination, and the other two children who were not IgG
positive were IgM positive (for the 12 children, 0 of 3, 1 of 3, and 2 of 4 were IgM positive at weeks 1, 2, and 3 after vaccination,
respectively). The exclusion of these 15 children likely did not bias
the results, given the high rates of IgM and IgG positivity after vaccination.
 |
DISCUSSION |
In this study, only 2% of persons had measles-specific IgM in the
first 7 days after primary measles vaccination. In addition, measles-specific IgM peaked at week 3 and was already declining by week
4. This finding explains the unexpectedly low IgM positivity rate of
73% we found at week 4 after vaccination in our previous study
conducted in the United States (7).
Only 14% of persons were IgG positive at 14 days after vaccination,
with the rate rising sharply at week 3 (81%) and reaching 85% by week
4. Although this rate of 85% is consistent with the expected
seroconversion rate of 85% in 9-month-old children from developing
countries (4, 5), data from Carson and colleagues (2) suggest that seroconversion rates may be higher when
sera are collected 6 to 8 weeks after vaccination compared with 4 to 5 weeks after vaccination. Because we collected few serum samples after
week 4 in this study, we do not know how many of the IgG-negative persons would have developed measles-specific IgG later than 4 weeks.
This study was conducted in a country where routine measles vaccination
is given earlier than in the United States (9 months versus 12 to 15 months) (1), with a subsequent lower seroconversion rate. It
is possible that in addition to the seroconversion rate, the timing of
IgM and IgG responses is affected by factors such as age, nutritional
status, and the type of vaccine used. Therefore, it would be useful to
repeat this study in the United States to verify the generalizability
of the findings. Even so, the results may still be helpful when
designing vaccine trials to optimize the likelihood of finding measles
IgM or IgG.
These findings may also help to guide the interpretation of positive
IgM results from persons with suspected measles who have been
vaccinated recently. For instance, the findings from this study suggest
that if persons with suspected measles have been vaccinated within 7 days of the onset of rash and are IgM positive according to this
antibody-capture IgM EIA, this IgM is probably due to wild-type measles
infection. Because blood samples were collected weekly, we have no
information about IgM results on days 8-13 after vaccination, and
therefore must assume for now that vaccine-induced IgM may be present
as early as 8 days after primary vaccination. We have previously
demonstrated in a U.S. cohort that IgM may persist until at least 8 weeks after primary measles vaccination for 10% of persons
(6). Combining the results from the previous study with the
current study, we conclude that an IgM-positive result obtained by this
antibody-capture IgM EIA may be difficult to interpret if sera are
collected between 8 days and 8 weeks after vaccination; in this
situation, the diagnosis of measles should be based on an epidemiologic
link to a confirmed case or on detection of wild-type measles virus.
 |
ACKNOWLEDGMENTS |
We acknowledge James Alexander for his assistance in study
design, Elizabeth Behaimanot for subject enrollment and data
collection, Kidane Woldeyesus for data entry, John O'Connor for his
editorial support, and Alisa Murray for her laboratory assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Respiratory and
Enteric Viruses Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd., NE, Mailstop A-34, Atlanta, GA 30333. E-mail: rzh7{at}cdc.gov.
 |
REFERENCES |
| 1.
|
American Academy of Pediatrics.
1997.
Measles, p. 344-357.
In
G. Peter (ed.), 1997 Red Book: report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village, Ill.
|
| 2.
|
Carson, M. M.,
D. W. Spady,
P. Albrecht,
J. A. Beeler,
J. Thipphawong,
L. Barreto,
K. M. Grimsrud, and H. F. Pabst.
1995.
Measles vaccination of infants in a well-vaccinated population.
Pediatr. Infect. Dis. J.
14:17-22[Medline].
|
| 3.
|
Erdman, D.,
L. Anderson,
D. Adams,
J. Stewart,
L. Markowitz, and W. Bellini.
1991.
Evaluation of monoclonal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus.
J. Clin. Microbiol.
29:1466-1471[Abstract/Free Full Text].
|
| 4.
|
Halsey, N. A.
1983.
The optimal age for administering measles vaccine in developing countries, p. 4-17.
In
N. A. Halsey, and C. De Quadros (ed.), Recent advances in immunization. A bibliographic review. Pan American Health Organization, Washington, D.C.
|
| 5.
|
Halsey, N. A.,
R. Boulos,
F. Mode,
J. Andre,
L. Bowman,
R. G. Yaeger,
S. Troureau,
J. Rohde, and C. Boulos.
1985.
Response to measles vaccine in Haitian infants 6 to 12 months old. Influence of maternal antibodies, malnutrition, and concurrent illnesses.
N. Engl. J. Med.
313:544-549[Abstract].
|
| 6.
|
Helfand, R. F.,
H. E. Gary, Jr.,
W. L. Atkinson,
J. D. Nordin,
H. L. Keyserling, and W. J. Bellini.
1998.
Decline of measles-specific immunoglobulin M antibodies after primary measles, mumps, and rubella vaccination.
Clin. Diagn. Lab. Immunol.
5:135-138[Abstract/Free Full Text].
|
| 7.
|
Helfand, R. F.,
J. L. Heath,
L. J. Anderson,
E. F. Maes,
D. Guris, and W. J. Bellini.
1997.
Diagnosis of measles with an IgM capture EIA: the optimal timing of specimen collection after rash onset.
J. Infect. Dis.
175:195-199[Medline].
|
| 8.
|
Hummel, K.,
D. Erdman,
J. Heath, and W. Bellini.
1992.
Baculovirus expression of the nucleoprotein gene of measles virus and utility of the recombinant protein in diagnostic enzyme immunoassays.
J. Clin. Microbiol.
30:2874-2880[Abstract/Free Full Text].
|
Clinical and Diagnostic Laboratory Immunology, March 1999, p. 178-180, Vol. 6, No. 2
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.